Neuropsychological and Behavioral Testing in Young Patients With Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by Children's Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Children's Oncology Group
ClinicalTrials.gov Identifier:
NCT00772200
First received: October 14, 2008
Last updated: February 24, 2014
Last verified: February 2014
  Purpose

This clinical trial is studying neuropsychological and behavioral testing in young patients with cancer. Collecting information over time from a series of tests may help doctors develop effective tests to measure neuropsychological and behavioral function in young patients with cancer.


Condition Intervention
Chemotherapeutic Agent Toxicity
Cognitive/Functional Effects
Neurotoxicity
Psychosocial Effects of Cancer and Its Treatment
Radiation Toxicity
Unspecified Childhood Solid Tumor, Protocol Specific
Other: questionnaire administration
Procedure: cognitive assessment
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Resource links provided by NLM:


Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Consistent, streamlined, and efficient administration of neuropsychological and behavioral tests [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Utilization of standardized battery of age-appropriate neuropsychological and behavioral tests in conjunction with COG Phase III clinical trials [ Time Frame: Baseline ] [ Designated as safety issue: No ]

Estimated Enrollment: 755
Study Start Date: September 2008
Estimated Primary Completion Date: January 2100 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Natural History (questionnaires)
Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient's function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.
Other: questionnaire administration Procedure: cognitive assessment Procedure: psychosocial assessment and care
Other Names:
  • psychosocial assessment
  • psychosocial assessment/care
  • psychosocial care
  • psychosocial care/assessment
  • psychosocial studies
Procedure: quality-of-life assessment
Other Name: quality of life assessment

Detailed Description:

OBJECTIVES:

I. To utilize a standardized battery of age-appropriate neuropsychological and behavioral tests in conjunction with Children's Oncology Group (COG) Phase III clinical trials to evaluate cognitive, social, emotional, and behavioral functioning over time.

II. To institute procedures to ensure a consistent, streamlined, and efficient administration of the neuropsychological/behavioral tests in a cooperative group setting in order to maximize compliance with a standardized assessment battery conducted at 3 standardized timepoints.

OUTLINE:

Parent and child participants complete the COG Standard Neuropsychological and Behavioral Battery testing at 9, 30, and 60 months post-diagnosis in a 1-hour session conducted by a neuropsychologist or psychologist. The Battery consists of tests of intelligence, processing speed/attention, memory, language preference, general developmental progress, attention and behavior/social/emotional function, executive function, adoptive function, and quality of life. Additionally, parents complete a parent-report questionnaire to gather information about patient's function in terms of attention, memory, executive abilities, and behavioral, social, and emotional adaption.

  Eligibility

Ages Eligible for Study:   1 Month to 21 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients diagnosed with cancer currently enrolled on COG therapeutic study.

Criteria

Inclusion Criteria:

  • Diagnosis of cancer
  • Must be currently enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning
  • Must have receptive and expressive English language skills
  • Patients with a history of severe or profound mental retardation (i.e. intelligence quotient [IQ] =< 50) are not eligible for enrollment

    • Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a specific learning disability (e.g. dyslexia) are eligible for this study
  • All patients and/or their parents or legal guardians must sign a written informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00772200

  Show 149 Study Locations
Sponsors and Collaborators
Children's Oncology Group
Investigators
Principal Investigator: Leanne Embry, MD Children's Oncology Group
  More Information

No publications provided

Responsible Party: Children's Oncology Group
ClinicalTrials.gov Identifier: NCT00772200     History of Changes
Other Study ID Numbers: ALTE07C1, NCI-2009-00383, COG-ALTE07C1, CDR0000594326, ALTE07C1, ALTE07C1, U10CA098543
Study First Received: October 14, 2008
Last Updated: February 24, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neurotoxicity Syndromes
Radiation Injuries
Nervous System Diseases
Poisoning
Substance-Related Disorders
Wounds and Injuries

ClinicalTrials.gov processed this record on July 22, 2014